http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Applied Therapeutics Announces Positive Data Trend in AT-007 ACTION-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format
-
Applied Therapeutics Announces Positive Data Trend in AT-007 ACTION-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format
-
Applied Therapeutics Reports Second Quarter 2022 Financial Results
-
Applied Therapeutics Reports Second Quarter 2022 Financial Results
-
Applied Therapeutics to Sponsor and Present at the 2022 Galactosemia Foundation Conference
-
Applied Therapeutics to Sponsor and Present at the 2022 Galactosemia Foundation Conference
-
Applied Therapeutics Inc. (APLT) Granted Orphan Medicinal Product Designation from the EMA for AT-007
-
Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia
-
Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia
-
Applied Therapeutics to Present at the UBS Global Healthcare Conference
-
Applied Therapeutics to Present at the UBS Global Healthcare Conference
-
Applied Therapeutics Reports First Quarter 2022 Financial Results
-
Applied Therapeutics Reports First Quarter 2022 Financial Results
-
Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society
-
Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society
-
Applied Therapeutics to Present at the 43rd Annual Meeting of the Society for Inherited Metabolic Disorders
-
Applied Therapeutics to Present at the 43rd Annual Meeting of the Society for Inherited Metabolic Disorders
-
Applied Therapeutics to Present at the 2022 Annual Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics
-
Applied Therapeutics to Present at the 2022 Annual Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics
-
Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences
-
Applied Therapeutics Supports 15th Annual Rare Disease Day
-
Applied Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
-
Applied Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
-
Applied Therapeutics (APLT) Provides Regulatory Update on Galactosemia Program, Says FDA Indicated Clinical Outcomes Data Will Likely be Required
-
Applied Therapeutics Provides Regulatory Update on Galactosemia Program
-
Applied Therapeutics Provides Regulatory Update on Galactosemia Program
-
Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency
-
Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency
-
Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism
-
Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism
-
Applied Therapeutics Reports Third Quarter 2021 Financial Results
-
Applied Therapeutics Reports Third Quarter 2021 Financial Results
-
Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency
-
Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency
-
Applied Therapeutics Reports Additional Pediatric Biomarker Data from ACTION-Galactosemia Kids
-
Applied Therapeutics Reports Additional Pediatric Biomarker Data from ACTION-Galactosemia Kids
-
Applied Therapeutics Inc. (APLT) Reports Initial Pediatric Biomarker Data from ACTION-Galactosemia Kids
-
Applied Therapeutics Reports Initial Pediatric Biomarker Data from ACTION-Galactosemia Kids
-
Applied Therapeutics Reports Initial Pediatric Biomarker Data from ACTION-Galactosemia Kids
-
Applied Therapeutics Reports Second Quarter 2021 Financial Results
-
Applied Therapeutics Reports Second Quarter 2021 Financial Results
-
Applied Therapeutics Added to Russell Microcap® Index
-
Applied Therapeutics Added to Russell Microcap® Index
-
Applied Therapeutics Announces Presentation of Data on the Prevalence of Diabetic Cardiomyopathy at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association
-
Applied Therapeutics Announces Presentation of Data on the Prevalence of Diabetic Cardiomyopathy at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association
-
Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association
-
Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association
-
Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics
-
Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics
-
Applied Therapeutics to Host Virtual Rare Disease Forum
